Our technology . Who we are. News Headlines for Helix BioPharma Corp. Common TSX Exchange | Aug 11, 2020, 5:52 PM EDT | Real-time price HBP $ 0.51 RT. RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. in the past year, with total shares outstanding growing by 19.5%.Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada.

Should you invest in Helix BioPharma (TSX:HBP)? (2) Number sourced from third party data provider. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. How experienced are the management team and are they aligned to shareholders interests?Who are the major shareholders and have insiders been buying or selling?Helix BioPharma Corp.'s company bio, employee growth, exchange listings and data sources© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. Dr. … ALL RIGHTS RESERVED.Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). How has Helix BioPharma's share price performed over time and what events caused price changes?Is Helix BioPharma undervalued compared to its fair value and its price relative to the market?How is Helix BioPharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?How has Helix BioPharma performed over the past 5 years?For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.What is Helix BioPharma current dividend yield, its reliability and sustainability? Adequate balance sheet with weak fundamentals. Helix BioPharma Corp. Common. Learn more Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included.Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development.

CHANGE -0.02 (-3.7736%) ... Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included. HBP's share price has been volatile over the past 3 months.HBP underperformed the Canadian Biotechs industry which returned 75.4% over the past year.HBP underperformed the Canadian Market which returned -1.2% over the past year.Insufficient data to calculate HBP's fair value to establish if it is undervalued.Insufficient data to calculate HBP's fair value to establish if it is undervalued. RICHMOND HILL, ON / ACCESSWIRE / July 31, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it will be presenting at the SNN Network Virtual Conference on Monday, August 3 rd at 2:30 PM EDT. We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.